Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.

摘要: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) enter clinical trials for treatment of solid tumors. The anti-tumor activity panitumumab has been tested in vitro and vivo, inhibition tumor growth observed numerous cancer models, particularly lung, kidney colorectal (CRC). Preclinical studies have established a role metastatic (mCRC) refractory multiple chemotherapeutic regimens. Based on these encouraging findings, was approved by US Food Drug Administration patients with epidermal factor receptor-expressing mCRC fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing improvement progression free survival (PFS) response rate (RR) produced monotherapy significantly greater non mutated (wild-type) K-RAS than those mutant K-RAS. Therefore implementing routine screening limiting use EGFR inhibitors wild-type appears better strategy select only who could benefit from therapy also may potential cost savings. purpose this review evaluate patient-related, disease-related economic-related evidence practice.